Mark Wilterding's most recent trade in RxSight Inc was a trade of 258,770 Stock Option (right to buy) done . Disclosure was reported to the exchange on Sept. 5, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| RxSight Inc | Mark Wilterding | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 05 Sep 2026 | 258,770 | 0 | - | - | Stock Option (right to buy) | |
| RxSight Inc | Mark Wilterding | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Sep 2026 | 258,770 | 258,770 | - | - | Stock Option (right to buy) | |
| RxSight Inc | Mark Wilterding | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2026 | 20,441 | 122,646 | - | - | Restricted Stock Unit | |
| RxSight Inc | Mark Wilterding | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2026 | 20,441 | 32,814 | - | - | Common Stock | |
| RxSight Inc | Mark Wilterding | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.96 per share. | 31 Aug 2026 | 7,765 | 25,049 | - | 7.0 | 54,044 | Common Stock |
| RxSight Inc | Mark Wilterding | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2026 | 20,441 | 143,087 | - | - | Restricted Stock Unit | |
| RxSight Inc | Mark Wilterding | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2026 | 20,441 | 20,441 | - | - | Common Stock | |
| RxSight Inc | Mark Wilterding | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.61 per share. | 28 Feb 2026 | 8,068 | 12,373 | - | 7.6 | 61,397 | Common Stock |
| RxSight Inc | Mark Wilterding | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2026 | 258,770 | 258,770 | - | - | Stock Option (right to buy) | |
| RxSight Inc | Mark Wilterding | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2026 | 163,528 | 163,528 | - | - | Restricted Stock Unit |